# Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer

> **NCT03571633** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Centre Leon Berard** · enrollment: 90 (estimated)

## Conditions studied

- HER2-positive Breast Cancer
- Operable Breast Cancer

## Interventions

- **DRUG:** Trastuzumab + Paclitaxel
- **DRUG:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT03571633
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-06
- **Primary completion:** 2027-01
- **Final completion:** 2027-09
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-11-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03571633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03571633, "Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT03571633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*